Status:
COMPLETED
The Role of Vitamin D3 in Pediatric Bronchiectasis Severity
Lead Sponsor:
Heba Omara
Conditions:
Cystic Fibrosis and Non CF Bronchiectasis
Eligibility:
All Genders
1-17 years
Phase:
PHASE2
PHASE3
Brief Summary
Vitamin D3 therapy was effective in decreasing the frequency of pulmonary exacerbations and preserving lung functions , thereby improving the disease severity even more in non CF than CF bronchiectasi...
Detailed Description
Objectives: To compare the effect of vitamin D3 on modifying the disease severity in CF and non CF bronchiectasis pediatric patients. Patients and Methods: This was a randomized clinical trial evalua...
Eligibility Criteria
Inclusion
- ages less than 18 years .
- Patients with documented diagnosis of CF (by the presence of a twice positive sweat chloride test and or paired CFTR DNA genetic mutations).
- Patients with non CF bronchiectasis diagnosed clinically and radiologically ( sweat chloride test negative) with a high resolution CT-confirmed diagnosis and clinical history consistent with bronchiectasis .
- Vitamin D deficient or insufficient CF and non CF bronchiectasis patients
Exclusion
- if they had
- sufficient Vitamin D level .
- chronic lung diseases other than CF and non CF bronchiectasis , liver or renal diseases.
- reported taking vitamin-D supplements or steroid therapy in the last 6 weeks.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04411901
Start Date
March 1 2018
End Date
March 20 2019
Last Update
June 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children hospital
Cairo, Abbasia, Egypt, 02